Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

PathAI Stock

Q: How to sell PathAI stock?

If you hold private company shares of PathAI - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your PathAI stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

pathai.comHealthcare / Digital HealthFounded: 2016Funding to Date: $255.49MM

PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient. This company was founded by Aditya Khosla and Andrew Beck in 2016 and is headquartered in Greater Boston Area, NE. PathAI services solve challenging pathology problems faced by the research and pharmaceutical industry.

Buy or sell PathAI stockLearn more about PathAI IPO

OverviewFinancingsValuation

Enterprise Value

Access PathAI’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like PathAI.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

PathAI investors also invested in these private companies

Tiger Global Management

ICON, Databricks, Groq, Waymo, Commonwealth Fusion, Scale AI, Ather Energy, Onestream, Flock Safety, Chime

Polaris Partners

Egnyte, FloQast, Automattic, Freenome, Capstan Therapeutics, PathAI, ByHeart, Cardurion Pharma, Art.com, Tome Biosciences

D1 Capital Partners

Anduril, Groq, Onestream, SKIMS, JUUL, Ramp, Bolt, Attentive, Wayve, Genesys

Kaiser Permanente

Abridge, Zepto, Health Catalyst, Freenome, Cedar, PathAI, Evidation Health, Solo.io, Incredible Health, Everytable

General Catalyst

Anduril, Mistral AI, Stripe, Canva, Circle, Helsing, Gusto, Grammarly, Ramp, Relativity Space

Team

Management Team

Andrew Beck

Co-Founder & Chief Executive Officer

Aditya Khosla

Co-Founder & Chief Technology Officer

Tiffany Freitas

Chief Business Officer

Andy Moffit

Chief People Officer

Board Members

Stanley Lapidus

Daktari Diagnostics

PathAI stock FAQs

Can you buy PathAI stock?

As PathAI is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like PathAI, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy PathAI stock?

To invest in a private company like PathAI through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell PathAI stock?

Yes, you may be able to sell your PathAI stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell PathAI stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your PathAI stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is PathAI a public company?

No, PathAI is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is PathAI’s stock price?

PathAI is a privately held company and therefore does not have a public stock price. However, you may access PathAI’s private market stock price with Forge Data.

What is PathAI’s stock ticker symbol?

PathAI does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Yahoo Finance 11/16/2023

PathAI Announces AISight Support of DICOM Standards and Commits to Being a Leader in Integrated Enterprise Image Architecture and Strategy

PathAI, a technology company specializing in AI-powered pathology solutions, has announced support for DICOM standards and aims to be a leader in integrated enterprise image architecture and strategy. This development marks a significant step towards PathAI's vision of interoperable pathology systems. The firm is also planning to launch its DICOMweb API, which will enhance its integration with organizations‚Äô enterprise image management and archive strategies.

Yahoo Finance 11/02/2023

PathAI Announces New NASH/MASH Advisory Network to Guide Evidence Generation and Regulatory Strategy for AI-Powered Digital Pathology Product Development

PathAI, a precision pathology solutions provider, has announced the creation of a NASH/MASH advisory network. The network, comprising international experts, will guide the development of AI-powered digital pathology products to improve outcomes for those with non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH). The advisory network's first meeting took place in September and will meet quarterly.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.